Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001104659-16-131412
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-07-07 06:04:02
Reporting Period:
2016-07-06
Filing Date:
2016-07-07
Accepted Time:
2016-07-07 06:04:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1556263 Syros Pharmaceuticals Inc. SYRS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1222012 Noubar Afeyan 1 Memorial Drive #7
Cambridge MA 02142
No No Yes No
1255927 Jr M Edwin Kania 1 Memorial Drive #7
Cambridge MA 02142
No No Yes No
1503559 Flagship Ventures Fund Iv, L.p. 1 Memorial Drive #7
Cambridge MA 02142
No No Yes No
1508051 Flagship Ventures Fund Iv General Partner Llc 1 Memorial Drive #7
Cambridge MA 02142
No No Yes No
1590973 Flagship Ventures Fund Iv-Rx, L.p. 1 Memorial Drive #7
Cambridge MA 02142
No No Yes No
1642578 Flagship Venturelabs Iv, Llc 1 Memorial Drive #7
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-07-06 213,333 $0.00 213,333 No 4 C Indirect See Footnote
Common Stock Acquisiton 2016-07-06 53,333 $0.00 53,333 No 4 C Indirect See Footnote
Common Stock Acquisiton 2016-07-06 1,066,666 $0.00 1,279,999 No 4 C Indirect See Footnote
Common Stock Acquisiton 2016-07-06 266,666 $0.00 319,999 No 4 C Indirect See Footnote
Common Stock Acquisiton 2016-07-06 1,600,000 $0.00 2,879,999 No 4 C Indirect See Footnote
Common Stock Acquisiton 2016-07-06 400,000 $0.00 719,999 No 4 C Indirect See Footnote
Common Stock Acquisiton 2016-07-06 474,661 $0.00 3,354,660 No 4 C Indirect See Footnote
Common Stock Acquisiton 2016-07-06 118,665 $0.00 838,664 No 4 C Indirect See Footnote
Common Stock Acquisiton 2016-07-06 320,000 $12.50 3,674,660 No 4 P Indirect See Footnote
Common Stock Acquisiton 2016-07-06 80,000 $12.50 918,664 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-1 Preferred Stock Disposition 2016-07-06 800,000 $0.00 213,333 $0.00
Common Stock Series A-1 Preferred Stock Disposition 2016-07-06 200,000 $0.00 53,333 $0.00
Common Stock Series A-2 Preferred Stock Disposition 2016-07-06 4,000,000 $0.00 1,066,666 $0.00
Common Stock Series A-2 Preferred Stock Disposition 2016-07-06 1,000,000 $0.00 266,666 $0.00
Common Stock Series A-3 Preferred Stock Disposition 2016-07-06 6,000,000 $0.00 1,600,000 $0.00
Common Stock Series A-3 Preferred Stock Disposition 2016-07-06 1,500,000 $0.00 400,000 $0.00
Common Stock Series B Preferred Stock Disposition 2016-07-06 1,779,981 $0.00 474,661 $0.00
Common Stock Series B Preferred Stock Disposition 2016-07-06 444,995 $0.00 118,665 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 213,332 Indirect See Footnote
Footnotes
  1. The Series A-1 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  2. The Series A-2 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  3. The Series A-3 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-3 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  4. The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  5. Held by Flagship Ventures Fund IV, L.P. ("Flagship IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons other than Flagship IV disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Stephane Bancel, a director of the Issuer, is a limited partner of Flagship IV and a member of Flagship IV LLC. Mr. Bancel disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
  6. Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons other than Flagship IV-Rx disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Stephane Bancel, a director of the Issuer, is a member of Flagship IV LLC. Mr. Bancel disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
  7. Held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship IV is the manager of VentureLabs IV. Flagship IV LLC is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV, Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by VentureLabs IV. Each of the filing persons other than VentureLabs IV disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Stephane Bancel, a director of the Issuer, is a limited partner of Flagship IV and a member of Flagship IV LLC. Mr. Bancel disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.